Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.

摘要: Increasing the intensity of induction chemotherapy has generated considerable recent interest in treatment acute myeloid leukemia. Achieving complete remission is a sine qua non condition for prolonged disease-free survival and may affect long-term outcome. In this setting, administering repeat course shortly after completion first course, known as timed-sequential (TSC), been tested lead to an improved Whether these results are due biologic recruitment cell cycle-specific agents unknown. However, strategy intensify more profound myelosuppression potential toxicities. Here we review chemotherapy, used regimen de novo, relapsed or refractory AML post-remission therapy, compare them with those from other types regimens.